BLRX.TA : Summary for BIOLINE RX LTD ILS0.01 - Yahoo Finance

U.S. Markets closed

BioLine Rx Ltd (BLRX.TA)


Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
Add to watchlist
318.50+3.00 (+0.95%)
At close: 4:24PM IDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close315.50
Open318.10
Bid316.00 x 255900
Ask316.50 x 42900
Day's Range316.00 - 321.40
52 Week Range2.88 - 321.40
Volume78,668
Avg. Volume182,123
Market Cap383.06M
BetaN/A
PE Ratio (TTM)-1,129.43
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswirelast month

    BioLineRx Reports Year End 2016 Financial Results

    TEL AVIV, Israel, March 23, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX,  TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results ...

  • PR Newswirelast month

    BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline

    BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has acquired Agalimmune Ltd., a private UK-based company with an innovative, anti-cancer immunotherapy platform. Acquisition consideration consisted of a $6 million upfront payment, of which $3 million is in cash and the remainder in BioLineRx shares. Additional future payments may be made based on development and commercial milestones.

  • PR Newswirelast month

    BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment

    BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, reported partial results data from its open-label Phase 2 trial for BL-8040 as a novel monotherapy approach for the mobilization and collection of blood forming stem and progenitor cells from the peripheral blood. The study consists of donor and patient pairs for allogeneic hematopoietic cell transplantation. The first part of the study, which is nearing completion, is intended to enroll an initial cohort of 10 donor and recipient pairs, consisting of patients with advanced hematological malignancies and their HLA-matched sibling donors.